Trial Profile
Dapagliflozin effectiveness on the vascular endothelial function and glycemic control in T2D with moderately inadequate glycemic control
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Nov 2018
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms DEFENCE
- 22 Nov 2018 Status changed from active, no longer recruiting to completed.
- 30 Sep 2016 Status changed from recruiting to active, no longer recruiting.
- 25 Aug 2015 New trial record